<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02071381</url>
  </required_header>
  <id_info>
    <org_study_id>DW340-1001</org_study_id>
    <nct_id>NCT02071381</nct_id>
  </id_info>
  <brief_title>Phase 1 Study of DDI Between DW330SR and DW1030 in Healthy Male Subjects</brief_title>
  <official_title>A Randomized, Open Label, Single-Dose, 6-sequence, 3-period, Crossover Study to Evaluate a Pharmacokinetic Drug Interaction Between DW330SR and DW1030 in Healthy Male Subjects</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Daewon Pharmaceutical Co., Ltd.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Daewon Pharmaceutical Co., Ltd.</source>
  <brief_summary>
    <textblock>
      The purpose of this study is to evaluate drugs interactions to compare pharmacokinetics in
      groups of monotherapy DW330SR, monotherapy DW1030, and coadministration DW330SR and DW1030
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>April 2014</start_date>
  <completion_date type="Actual">June 2014</completion_date>
  <primary_completion_date type="Actual">June 2014</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <primary_outcome>
    <measure>Trans-OH as Main Metabolites of DW330SR, DW330SR, Cmax, AUClast of DW1030</measure>
    <time_frame>-28 ~ -2day(screening), -1day, 1day, 2day</time_frame>
  </primary_outcome>
  <number_of_arms>3</number_of_arms>
  <condition>Healthy</condition>
  <arm_group>
    <arm_group_label>A</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>only DW330SR 45mg</description>
  </arm_group>
  <arm_group>
    <arm_group_label>B</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>only DW1030 75mg</description>
  </arm_group>
  <arm_group>
    <arm_group_label>C</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>DW330SR 45mg and DW1030 75mg</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>DW330SR 45mg</intervention_name>
    <arm_group_label>A</arm_group_label>
    <arm_group_label>C</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>DW1030 75mg</intervention_name>
    <arm_group_label>B</arm_group_label>
    <arm_group_label>C</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Healthy Adult males aged 20~40 years at screening visit

          -  Subjects with range of 19 kg/m2 ~ 27 kg/m2 as BMI measurements at screening visit

          -  Subjects with BP range of below:

             90 mmHg ≤ Systolic BP ≤ 140 mmHg 50 mmHg ≤ Diastolic BP ≤ 90mmHg

          -  Subjects who voluntarily agreed with written consent that be able to understand the
             objective, method of the study, the characteristics of investigational drug, and
             comply with the reguirement of the study

        Exclusion Criteria:

          -  Subjects with clinically significant disease or history such as Liver, kidney,
             gastrointestinal, respiratory, musculoskeletal, endocrine, nervous psychiatric, blood
             tumor system and cardiovascular. (In particular, bronchial asthma, severe hepatic,
             renal failure, severe blood disorders, severe myasthenia gravis, cardiac dysfunction,
             peptic ulcer, etc.)

          -  Subjects with history of gastrointestinal disease (ex, Chrones dz, peptic ulcer, etc)
             affect the absorption of Investigational drugs or history of surgery (except for a
             simple appendectomy or hernia surgery)

          -  Subjects with hypersensitivity reaction or clinically significant disease in drugs
             (Aspirin, NSAID and antibiotics) including ingredient of DW330SR and DW1030 and Food
      </textblock>
    </criteria>
    <gender>Male</gender>
    <minimum_age>20 Years</minimum_age>
    <maximum_age>40 Years</maximum_age>
  </eligibility>
  <location>
    <facility>
      <name>Asan Medical Center IRB</name>
      <address>
        <city>Seoul</city>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Korea, Republic of</country>
  </location_countries>
  <verification_date>January 2014</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>February 21, 2014</study_first_submitted>
  <study_first_submitted_qc>February 23, 2014</study_first_submitted_qc>
  <study_first_posted type="Estimate">February 25, 2014</study_first_posted>
  <last_update_submitted>March 26, 2015</last_update_submitted>
  <last_update_submitted_qc>March 26, 2015</last_update_submitted_qc>
  <last_update_posted type="Estimate">March 30, 2015</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

